

Different patients. Different needs.
For appropriate patients, it may be time to consider a switch to IXINITY®.
There are many reasons why patients may need to switch their factor IX treatment. See why these patients made the switch, and decide if IXINITY may be right for patients in your practice.

The confident control Nathan needs
Nathan, severe hemophilia B
Nathan’s Factor IX History
• Frequent bleeds
• Multiple infusions to resolve bleeds
• Lack of motivation/confidence to be active
“In the past, I felt somewhat shackled by what life was like with hemophilia. I’ve had a lot of bleeds. I was infusing a lot.”
Reasons for switching to IXINITY
- Coverage to plan ahead and be more active
- IXINITY is a standard half-life factor IX that fits his active lifestyle
- No longer feels held back by his hemophilia—more willing to “jump in and go” because he’s confident that he’s covered with IXINITY
In a clinical trial of IXINITY, 71% of bleeds were resolved with 1 infusion.1 The number of days between dosing may vary. Individual response may vary.
This information is based on Nathan’s experience. Different patients may have different results.

The opportunity for Marcus to live actively
Marcus, severe hemophilia B
Marcus’ Factor IX History
• Frequent bleeds
• Lack of control
• Limited activity/independence
“For the longest time, I wasn’t getting the bleed control I wanted. It just wasn’t happening.”
Reasons for switching to IXINITY
- An active lifestyle
- 24-hour terminal half-life1 gives him the bleed control he needs for his active, everyday lifestyle
In a clinical trial of IXINITY, 71% of bleeds were resolved with 1 infusion.1 The number of days between dosing may vary. Individual response may vary.
This information is based on Marcus’ experience. Different patients may have different results.

Reliable coverage means less stress for Joe
Joe, severe hemophilia B
Joe’s Factor IX History
• Worried over lack of bleed control
• Sedentary lifestyle
• Fearful of surgical procedures
“In the past, although I was infusing regularly, I’d still have breakthrough bleeds.”
Reasons for switching to IXINITY
- Confidence in coverage
- Proven bleed prevention and control gave Joe the confidence he needed to go about his everyday life without having to worry when he wants to go on a hike or change a tire
- Motivation to move
- The 0.98 IU/dL mean incremental recovery and 24-hour half-life of IXINITY1 help Joe achieve peak factor levels when he needs them, so he doesn’t have to worry about if—or when—he’s covered
IXINITY was rated as adequate or better in controlling hemostasis post surgery as assessed by the surgeon.1
This information is based on Joe’s experience. Different patients may have different results.

The positive experience Felix was seeking
Felix, severe hemophilia B
Felix’s Factor IX History
• Unhappy with current treatment
• Seeking bleed control coverage
• Desire to make a difference
“Growing up with hemophilia was scary and hard sometimes.”
Reasons for switching to IXINITY
- A common cause
- The support and commitment of IXINITY representatives to the hemophilia community matched his own dedication and drive to make a difference
This information is based on Felix’s experience. Different patients may have different results.

A turning point in Joel’s treatment
Joel, hemophilia B
Joel’s Factor IX History
• Struggled finding factor support
• Frustrated with stereotypes about women with hemophilia B
• Experienced frequent mouth bleeds
“I’ve had bleeding issues since I was a child, but they became hard to ignore.”
Reasons for switching to IXINITY
- A shift in the stereotype
- The Medexus commitment to women and validation of her condition created a fundamental life change for Joel
- Flexibility that fits
- Joel can plan her infusions and dental procedures to get a good night’s sleep. Not waking up to spontaneous mouth bleeds made a difference thanks to the 24-hour half-life of IXINITY1
This information is based on Joel’s experience. Different patients may have different results.
Reference: 1. IXINITY [coagulation factor IX (recombinant)] prescribing information. Chicago, IL: Aptevo BioTherapeutics LLC; September 2020.